Navigation Links
Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
Date:12/17/2009

n the countries in which Labopharm is seeking regulatory approval represent 23% of the immediate release tramadol-acetaminophen combination products market in Europe for the 12-month period ending September 30, 2009.

About Labopharm's Twice-Daily Tramadol-Acetaminophen

Tramadol-acetaminophen products leverage the unique but complementary modes of action of each of the active ingredients to provide the analgesic strength of a mild opioid (tramadol) and the rapid pain relief of acetaminophen. Tramadol-acetaminophen combination products were first launched in 2001 in the United States and in 2003 in other major markets around the world.

Labopharm's unique formulation of tramadol-acetaminophen is based on its Contramid(R) controlled-release technology, which provides patients with both rapid pain relief and analgesic strength in a sustained-relief analgesic. The Company's twice-daily formulation of tramadol-acetaminophen is designed to provide improved patient benefit by controlling the release of the two active ingredients simultaneously, thereby providing both immediate and sustained relief of acute pain.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. and Canada. The Company's third product is under regulatory review in Europe. Labopharm also has a pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally dev
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Abilene, Texas (PRWEB) July 25, 2014 Yisrayl ... posted a new article on his blog explaining why so ... are needed the most. , In the article, Yisrayl ... going out and shares the results. For example, in one ... displayed all over church grounds to pray for rain; ironically, ...
(Date:7/25/2014)... 25, 2014 Yisrayl Hawkins, Pastor and Overseer ... again stirring the pot by revealing to the whole world, ... into worshipping Satan, the devil, in his new article. , ... by Satan, and carried out by the Catholic Church. He ... from the Inspired Holy Scriptures and replacing it with titles ...
(Date:7/25/2014)... According to the Hemorrhoid ... Vkool.com, this is a comprehensive guide that ... common types of hemorrhoids including:, ...     Young children with hemorrhoids , ...     Very large hemorrhoids and chronic hemorrhoids , ...
(Date:7/25/2014)... Myers, FL (PRWEB) July 25, 2014 ... iPhones, iPods, and iPads. The app provides a tailored ... painful and potentially dangerous sunburns and skin damage. In ... the sights, sounds, and capabilities of iTanSmart. , ... describing the app as a ‘better organized’ and ‘great ...
(Date:7/25/2014)... Los Angeles California (PRWEB) July 25, 2014 ... STD status of all its members and found that there ... living with the HSV and/or HPV virus. , Living with ... not the end, as there are many people from all ... lives despite having been diagnosed with one of many STDs ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says Prayers for Rain Result in Violent Hail Because Prayers Are Not Being Heard in New Post 2Health News:Yisrayl Hawkins Says Prayers for Rain Result in Violent Hail Because Prayers Are Not Being Heard in New Post 3Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:The Number of People Living With HSV and HPV Greatly Increased- Survey on PositiveSingles.com 2
... ... - Gross margin expanded to 32.4 percent from ... Health management segment revenue grew 25 percent, - Net earnings: ... Nov. 3 Health Fitness,Corporation (NYSE Alternext US: FIT), a leading provider ...
... Held on Thursday November 6 at 8:30,a.m., NEW ... Board: VION) today announced financial,results for the three-month and ... a net loss of $6.8 million, or $0.92 per ... to a net loss,of $9.0 million, or $1.33 per ...
... neck, government study finds , , MONDAY, Nov. 3 (HealthDay ... with human papillomavirus (HPV) occurred in 38 states and ... officials reported Monday. , HPV is a group of ... than 30 of which can be sexually transmitted. Most ...
... A recent study conducted by researchers at Georgia ... demonstrate that administration of preemptive morphine prior to a ... of pain in adult rodents. These studies have ... administered to neonates prior to surgery. Infant rodents that ...
... Center at the University of California, San Diego (UCSD) ... at revving up the immune system to combat a ... therapy is being offered to patients with chronic lymphocytic ... resistant to initial treatment or harbors a particular chromosomal ...
... Revenue for the third quarter 2008 increases 32% to $16.0 million. - Heart ... surgical ablation products revenue grows 21.7%. ... Company raises lower end of its 2008 revenue guidance to $65 - $66 ... ...
Cached Medicine News:Health News:HealthFitness Announces 2008 Third Quarter Results 2Health News:HealthFitness Announces 2008 Third Quarter Results 3Health News:HealthFitness Announces 2008 Third Quarter Results 4Health News:HealthFitness Announces 2008 Third Quarter Results 5Health News:HealthFitness Announces 2008 Third Quarter Results 6Health News:HealthFitness Announces 2008 Third Quarter Results 7Health News:HealthFitness Announces 2008 Third Quarter Results 8Health News:HealthFitness Announces 2008 Third Quarter Results 9Health News:HealthFitness Announces 2008 Third Quarter Results 10Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 2Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 3Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 4Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 5Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:GSU study first to confirm long-term benefits of morphine treatment in infants 2Health News:Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients 2Health News:ATS Medical Announces Third Quarter Results 2Health News:ATS Medical Announces Third Quarter Results 3Health News:ATS Medical Announces Third Quarter Results 4Health News:ATS Medical Announces Third Quarter Results 5Health News:ATS Medical Announces Third Quarter Results 6Health News:ATS Medical Announces Third Quarter Results 7Health News:ATS Medical Announces Third Quarter Results 8
(Date:7/25/2014)... /PRNewswire-iReach/ -- Dr. Michael Gabriel of a prominent ... a recent study, which shows how grief in pregnancy may ... According to US News , ... likely than others to grow up overweight or obese, even ... were two specific types of stress that caused obesity: "Children ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... 15 Concentra, the largest,occupational health care provider ... campaign to educate America,s workforce about the flu, ... it. The company expects to vaccinate,nearly 300,000 people ... in lost productivity. Concentra Medical Centers offers ...
... Patients with,mid-range coronary artery disease are more likely ... have repeat procedures if they get bypass,surgery rather than ... new report by the Agency for Healthcare Research and ... Services. The analysis drew on 23 randomized controlled ...
Cached Medicine Technology:Concentra Offers Flu Vaccines to Keep America Working 2Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease 2Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease 3
... is a basic laboratory system for pH ... can be obtained when used with a ... • Fast and easy one and two-point ... five buffers (pH 1.68, 4.00, 7.00, 10.01 ...
... Multimode Detectors provide unmatched value and ... and automation needs. Capable of performing ... the same instrument, the DTX Series ... can be integrated seamlessly with Beckman ...
... is a dual-monochromator, multi-detection microplate reader ... 6-384 microplate reading capability. Detection modalities ... intensity (FI) and have optical performance ... or spectrophotometer. Endpoint, kinetic, spectrum and ...
... microplate reader combines improved flexibility ... with a wide range of ... the flexibility, sensitivity and high ... is the ideal detection solution ...
Medicine Products: